NCT07306962 Virtual Lesion Segmentation and Mandibular Ameloblastoma Radiographic Safety Margin
| NCT ID | NCT07306962 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Alexandria University |
| Condition | Ameloblastoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 10 participants |
| Start Date | 2025-01-01 |
| Primary Completion | 2026-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 10 participants in total. It began in 2025-01-01 with a primary completion date of 2026-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Reconstruction of segmental mandibular defects is in a continuous state of evolution utilizing the recent advances in Computer-Aided Designing (CAD) and preoperative Virtual Surgical Planning (VSP). The anterior iliac crest is one of the ideal reservoirs for autogenous harvesting of a bi-cortical bone block with 1:1 cortical to cancellous bone ratio which is optimal for rapid and predictable consolidation. The aim of this study is the utility of VSP guided by CT and confirmation by histopathological analysis in achieving negative margins and preventing recurrence of mandibular ameloblastoma.
Eligibility Criteria
Inclusion Criteria: 1. Patients with histologically confirmed ameloblastoma using a preoperative biopsy. 2. Patients with ameloblastoma that require segmental mandibular continuity defect, not involving the condyle. Exclusion Criteria 1. Patients with lateral segmental mandibular defect involving the condyle. 2. Patients with an active infection at the site of resection. 3. Patients with recurrent lesion after resection.
Contact & Investigator
yehia A El-Mahallawy, PhD
PRINCIPAL INVESTIGATOR
Faculty of Dentistry, Alexandria University, Alexandria, Alexandria
Frequently Asked Questions
Who can join the NCT07306962 clinical trial?
This trial is open to participants of all sexes, studying Ameloblastoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07306962 currently recruiting?
Yes, NCT07306962 is actively recruiting participants. Contact the research team at yehia.el-mahallawy@alexu.edu.eg for enrollment information.
Where is the NCT07306962 trial being conducted?
This trial is being conducted at Alexandria, Egypt.
Who is sponsoring the NCT07306962 clinical trial?
NCT07306962 is sponsored by Alexandria University. The principal investigator is yehia A El-Mahallawy, PhD at Faculty of Dentistry, Alexandria University, Alexandria, Alexandria. The trial plans to enroll 10 participants.